CHICAGO, Ill. (April 1, 2008) — A new study has found that an x-ray dye intended to reduce stress on the kidneys did not prevent renal injury during percutaneous coronary intervention (PCI) in patients who already had compromised kidney function. In addition, it made no difference in the need for dialysis or in the length of hospital stay, according to the Contrast Media and Nephrotoxicity Following Coronary Revascularization by Angioplasty (CONTRAST) study.
The CONTRAST study is being reported today in a Late-Breaking Clinical Trials session at the SCAI Annual Scientific Sessions in Partnership with ACC i2 Summit (SCAI-ACCi2) in Chicago. SCAI-ACCi2 is a scientific meeting for practicing cardiovascular interventionalists sponsored by the Society for Cardiovascular Angiography and Interventions (SCAI) in partnership with the American College of Cardiology (ACC).
Some earlier studies have shown that iodixanol (Visipaque) reduces the risk of kidney damage when moderate doses of x-ray dye, or contrast medium, are used, mainly during diagnostic angiography. This is the first randomized trial to look exclusively at PCI, which involves far higher doses of contrast medium.
source:Society for Cardiovascular Angiography and Interventions
No comments:
Post a Comment